The Union Health Ministry will launch a nationwide HPV vaccination program targeting girls aged 14.
The vaccination will be voluntary, free of cost, and ensure equitable access.
Gardasil, a quadrivalent HPV vaccine, will be used to protect against HPV types 16, 18, 6, and 11.
Cervical cancer is the second most common cancer among women in India, with nearly 80,000 new cases reported annually.
The HPV vaccine has shown 93–100% effectiveness in preventing cervical cancer caused by vaccine-covered HPV types.
Detailed Insights:
The HPV vaccination program aims to prevent HPV infection before it can progress to cervical cancer, addressing a significant health challenge for women in India.
India secured HPV vaccine supplies through a transparent, globally supported procurement mechanism in partnership with Gavi, the Vaccine Alliance.
HPV vaccination will be conducted at designated government health facilities, including Ayushman Arogya Mandirs, Community Health Centres, and District Hospitals.
Each vaccination session will be carried out by trained medical officers and healthcare teams, equipped for post-vaccination observation and management of any adverse events.
Over 90 countries are implementing single-dose HPV vaccination schedules to improve coverage and affordability.
Key Concepts Involved:
HPV (Human Papillomavirus): A common viral infection that can cause cervical cancer and other diseases.
Gardasil: A quadrivalent HPV vaccine that protects against HPV types 16, 18, 6, and 11.
Cervical Cancer: A type of cancer that occurs in the cells of the cervix, often caused by HPV.